1. Is There Use for FDG-PET in Prostate Cancer?
- Author
-
Hossein Jadvar
- Subjects
Oncology ,PCA3 ,Male ,medicine.medical_specialty ,Treatment response ,Disease ,Malignancy ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Fluorodeoxyglucose F18 ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Neoplasm Staging ,medicine.diagnostic_test ,business.industry ,Fdg uptake ,Prostatic Neoplasms ,medicine.disease ,carbohydrates (lipids) ,Treatment Outcome ,Positron emission tomography ,030220 oncology & carcinogenesis ,Positron-Emission Tomography ,Radiology ,Prostate gland ,business - Abstract
The utility of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in prostate cancer depends on the phase of the disease along the natural history of this prevalent malignancy in men. Incidental high FDG uptake in the prostate gland, while rare, should prompt further investigation with at least a measurement of serum prostate specific antigen (PSA) level. While in general FDG uptake level may significantly overlap among normal, benign, and malignant tissues, aggressive primary tumors with Gleason score greater than 7 tend to display high FDG uptake. PET with FDG may be useful in staging of those patients with aggressive primary tumors and can localize the site of disease in a small fraction of men with biochemical failure and negative conventional imaging studies. FDG PET may be quite useful in treatment response assessment and prognostication of patients with castrate-resistant metastatic prostate cancer.
- Published
- 2016